Psychopharmacological Treatment of Depression,Anxiety,Irritability and Insomnia in Patients Receiving Interferon-α: a Prospective Case Series and a Discussion of Biological Mechanisms

Abstract

We studied 60 patients receiving a 1-year course of interferon (IFN)-αtherapy for chronic viral hepatitis. Patients underwent psychiatric assessment before starting the IFN-αtherapy, and monthly throughout the therapy, using the Structured Clinical Interview for the DSM-III-R, the 17-item Hamilton Depression Rating Scale, the Beck Depression Inventory and the Spielberg State and Trait Anxiety Inventory. Five patients had a baseline diagnosis of major depression and 18 (30%) developed an IFN-α-induced psychiatric adverse effect; 12 of these 23 patients received psychopharmacological treatment (patients and clinicians jointly decided the need for treatment). Two of the five patients with baseline depression started an antidepressant treatment (paroxetine) together with the IFN-α and successfully completed the IFN-αtherapy. Ten patients received treatment for the IFN-α-induced psychiatric adverse effects (depression in five patients, anxiety in two patients, severe irritability in two patients and insomnia in one patient). Depression was treated with paroxetine, amisulpride or levosulpiride; anxiety and insomnia were treated with benzodiazepines; and irritability was treated with thioridazine. Individual response to medications was measured with the Clinical Global Impression scale. Of the patients with IFN-α-induced depression, two received paroxetine (one showed a good response), two received amisulpride (one showed a good response) and one did not respond to levosulpiride but responded to paroxetine. The patients experiencing anxiety or insomnia responded well to benzodiazepines. One patient showed a good response, and one a poor response, to thioridazine for irritability. Only one patient interrupted the therapy because of psychiatric adverse effects. Overall, the 12 patients that received psychopharmacological treatment developed less severe psychopathological symptoms during the IFN-αtherapy compared to the 11 patients who had untreated baseline depression or untreated IFN-α-induced psychiatric adverse effects. Thus, psychopharmacological management can successfully treat psychiatric symptoms in patients who are receiving IFN-α.

Get full access to this article

View all access options for this article.

References

Alter M J (1997) Epidemiology of hepatitis C . Hepatology 26: 625–655

American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd rev. edn. American Psychiatric Press, Washington, DC

Beck A T, Ward C H, Mendelson M, Mock J, Erbaugh J (1961). An inventory for measuring depression . Arch Gen Psychiatry 5: 561–571

Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, Almerighi C, Levrero M, Egyed B, Bosmans E, Meltzer H Y, Maes M (2001) Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms . Psychiatry Res 105: 45–55

Byrne G, Lehmann L, Kirshbaum J, Borden E, Lee C, Brown R (1986) Induction of tryptophan degradation in vitro and in vivo: a gamma inter-feron stimulated activity . J Interferon Res 6: 389–396

Capuron L, Ravaud A, Neveu P J, Miller A H, Maes M, Dantzer R (2002a) Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy . Mol Psychiatry 7: 468–473

Capuron L, Gumnick J F, Musselman D L, Lawson D H, Reemsnyder A, Nemeroff C B, Miller A H (2002b) Neurobehavioural effects of inter-feron-a in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions . Neuropsychopharmacology 26: 643–652

Carpiniello B, Orrù M G, Baita A, Pariante C M, Farci G (1998) Mania induced by withdrawal of treatment with interferon-alpha . Arch Gen Psychiatry 55: 88–89

Cassidy E M, O’Keane V (2000) Depression and interferon-alpha therapy . Br J Psychiatry 176: 494

10.

Cassidy E M, Manning D, Byrne S, Bolger E, Murray F, Sharifi N, Wallace E, Keogan M, and O’Keane V (2002) Acute effects of low-dose inter-feron-a on serum cortisol and plasma interleukin-6 . J Psychopharmacol 16: 230–234

11.

Farah A (2002) Interferon induced depression treated with citalopram . J Clin Psychiatry 63: 166–167

12.

Gleason O C, Yates W R (1999) Five cases of interferon-alpha-induced depression treated with antidepressant therapy . Psychosomatics 40: 510–512

13.

Guy W (1976) ECDEU assessment manual for psychopharmacology. US Department of Health, Education and Welfare, Bethesda, MD

14.

Hamilton, M. (1960). A rating scale for depression . J Neurol Neurosurg Psychiatry 23: 56–62

15.

Hauser P, Khosla J, Aurora H, Laurin J, Kling M A, Hill J, Gulati M, Thornton A J, Schultz R L, Valentine A D, Meyers C A, Howell C D (2002) A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorders in patients with hepatitis C . Mol Psychiatry 7: 942–947

16.

Kraus M R, Schafer A, Faller H, Csef H, Scheurlen M (2002) Paroxetine for the treatment of interferon-a induced depression in chronic hepatitis C . Aliment Pharmacol Ther 16: 1091–1099

17.

Lamberts S W J (1996) The glucocorticoid insensitivity syndrome . Hormone Res 45 (Suppl 1): 2–4

18.

Levenson J L, Fallon H J (1993) Fluoxetine treatment of depression caused by interferon-alpha . Am J Gastroenterol 88: 760–761

19.

Lingford-Hughes A, Nutt D (2003) Neurobiology of addiction and implications for treatment . Br J Psychiatry 182: 97–100

20.

Maddock C, Pariante C M (2001) How does stress affect you? An overview of stress, immunity, depression, and disease . Epidemiol Psychiatr Soc 10: 153–162

21.

Maes M, Song C, Lin A H, Bonaccorso S, Kenis G, De Jongh R, Bosmans E, Scharpé S (1999) Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion . Neuropsychopharmacology 20: 370–379

22.

McAllister-Williams R H, Young A H, Menkes D B (2000) Antidepressant response reversed by interferon . Br J Psychiatry 176: 93

23.

Menkes D B, MacDonald J A (2000) Interferons, serotonin and neurotoxi-city . Psychol Med 30: 259–268

24.

Meyers C A, Valentine A D (1995) Neurological and psychiatric adverse effects of immunological therapy . CNS Drugs 3: 56–68

25.

Miller A H, Pariante C M, Pearce B D (1999) Effects of cytokines on glucocorticoid receptor expression and function: glucocorticoid resistance and relevance to depression . Adv Exp Med Biol 461: 107–116

26.

Montgomery SA (2002) Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders . Int Clin Psychopharmacol 17 (Suppl 4): S9–S15

27.

Morikawa O, Sakai N, Obara H, Saito N (1998) Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter . Eur J Pharmacol 349: 317–324

28.

Musselman D L, Lawson D H, Gumnick J F, Manatunga A K, Penna S, Goodkin R S, Greiner K, Nemeroff C B, Miller A H (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa . N Engl J Med 344: 961–966

29.

Nozaki O, Takagi C, Takaoka K, Takata T, Yoshida M (1997) Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: an overview of cases in Japan . Psychiatry Clin Neurosci 51: 175–180

30.

Pariante C M, Pearce B D, Pisell T L, Owens M J, Miller A H (1997) Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine . Mol Pharmacol 52: 571–581

31.

Pariante C M, Orrù M G, Baita A, Farci M G, Carpiniello B (1999a) Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders . Lancet 354: 131–132

32.

Pariante C M, Pearce B D, Pisell T L, Sanchez C I, Po C, Su C, Miller A H (1999b) The pro-inflammatory cytokine, interleukin-1 alpha, reduces glucocorticoid receptor translocation and function . Endocrinology 140: 4359–4366

33.

Pariante C M, Miller A H (2001a) Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment . Biol Psychiatry 49: 391–404

34.

Pariante C M, Makoff A, Lovestone S, Feroli S, Heyden A, Miller A H, Kerwin R W (2001b) Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters . Br J Pharmacol 134: 1335–1343

35.

Pariante C M, Landau S, Carpiniello B (2002) Interferon-alfa-induced adverse effects in patients with a psychiatric diagnosis . N Engl J Med 347: 148–149

36.

Pariante C M, Hye A, Williamson R, Makoff A, Lovestone S, Kerwin R W (2003a) The antidepressant, clomipramine, regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones . Neuropsychopharmacology 28: 1553–1561

37.

Pariante C M, Kim R B, Makoff A, Kerwin R W (2003b) Fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters . Br J Pharmacology 139: 1111–1118

38.

Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski J P (1996) Meta-analysis of interferon randomised trials in the treatment of viral hepatitis C: effects of dose and duration . Hepatology 24: 778–789

39.

Renault P F, Hoofnagle J H, Park Y, Mullen K D, Peters M, Jones B, Rustgi V, Jones E A (1987) Psychiatric complications of long-term interferon-alpha therapy . Arch Int Med 147: 1577–1580

40.

Schramm T M, Lawford B R, Macdonald G A, Cooksley W G (2000) Sertraline treatment of interferon-alpha induced depressive disorder . Med J Aust 173: 359–361

41.

Spielberg CD, Gorsuch RL, Lushene RE (1968) State-trait anxiety inventory, form X. Consulting Psychologist Press, Palo Alto, CA

42.

Spitzer R L, Williams J B, Gibbon M, First M B (1992) The Structured Clinical Interview for DSM-III-R (SCID): I. History, rationale and description . Arch Gen Psychiatry 49: 624–629

43.

Taylor D, McConnell H, Duncan-McConnell D, Kerwin R (2001) The Maudsley prescribing guidelines, 6th edn. Martin Dunitz Ltd, London

44.

Valentine A D, Meyers C A, Kling M A, Richelson E, Hauser P (1998) Mood and cognitive side effects of interferon-alpha therapy . Semin Oncol 25 (Suppl 1): 39–47

45.

Zdilar D, Franco-Bronson K, Buchler N, Locala J A, Younossi Z M (2000) Hepatitis C, interferon-alpha, and depression . Hepatology 31: 1207–1211